Compliance is an integral part of the entire biopharma, medical device and product lifecycle, yet it poses one of the biggest challenges for our customers. While they try to focus on driving value, innovation and patient centricity, customers find that much of their efforts and finances are still being invested in managing regulatory obligations. Challenges are spread across internal factors, such as obsolete and disconnected platforms, multiple silos and manual processes, to external factors like the changing regulatory landscape and increased scrutiny of regulators. These challenges prevent our customers from moving the needle of compliance from cost to value.
In building an integrated compliance platform, EVERSANA has addressed the market dynamics that challenge clients’ ability to provide real insight to products, innovation and patient centricity. Nina Lahanis, Associate Vice President, Safety Science, discusses how our holistic model advances life sciences compliance to deliver and commercialize safer and better products, allowing customers to stay focused on what matters most: helping patients live healthy lives.
[Fill out the form below to learn more]
Nina Patel Lahanis has a strong background in global pharmacovigilance, medical communications, regulatory compliance, medical education and technology. With 10+ years of pharmacovigilance expertise and more than 25 years in biotech/pharma R&D and marketing, Nina’s leadership expertise spans…